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Abstract: Carrageenans are thickening and gelling agents that may provide health benefits. Iota
(ι)-carrageenan, a linear sulfated polysaccharide, is produced by the red seaweed, Sarconema filiforme.
This study investigated the potential of this seaweed as a functional food for the reversal of metabolic
syndrome and possible mechanisms. Male Wistar rats were divided into four groups in a 16-week
protocol: corn starch diet-fed rats (C); C rats supplemented with 5% S. filiforme for the last 8 weeks
(CSF); high-carbohydrate, high-fat diet-fed rats (H); and H rats supplemented with 5% S. filiforme
for the last 8 weeks (HSF). S. filiforme was produced in tank-based aquaculture yielding 27 g dry
weight/day/m2 of culture area. H rats developed obesity, hypertension, dyslipidaemia, glucose
intolerance, fatty liver and increased left ventricular collagen deposition. S. filiforme supplementation
decreased body weight, abdominal and liver fat, systolic blood pressure, plasma total cholesterol
concentrations, and plasma activities of alanine transaminase and aspartate transaminase. S. filiforme
supplementation modulated gut microbiota without changing the Firmicutes to Bacteroidetes ratio.
S. filiforme improved symptoms of high-carbohydrate, high-fat diet-induced metabolic syndrome in
rats. Possible mechanisms include a reduced infiltration of inflammatory cells into organs as well as
prebiotic actions in the gastrointestinal tract.
Keywords: algae; Sarconema filiforme; sulfated polysaccharides; ι-carrageenan; prebiotics; gut
microbiota; aquaculture; nutraceutical
1. Introduction
Carrageenans are a group of high molecular weight (>100 kDa) sulfated polygalactans isolated
from red seaweeds (Rhodophyceae) that are “generally regarded as safe” for routine use as gelling and
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thickening agents in foods [1]. The three types of carrageenans, named kappa (κ), iota (ι) and lambda (λ),
have one, two and three sulfate groups per disaccharide unit, respectively [1]. The major commercially
cultivated warm-water species for carrageenans are Kappaphycus alvarezii and Eucheuma denticulatum [2],
producing κ- and ι-carrageenans, respectively. These seaweeds are grown on a commercial scale
primarily in Indonesia, the Philippines, Malaysia, Brazil and Tanzania [3]. Sarconema filiforme is a red
seaweed containing ι-carrageenan, distributed throughout the tropical and subtropical Indo-Pacific,
including along the eastern and western coasts of Australia [4,5].
The health benefits of red seaweeds include obesity reduction, decreased lipid absorption and
modification of the binding of cholesterol in the gastrointestinal tract thereby reducing cardiovascular
disease risk [1,6]. However, there have been no studies on Sarconema species or their major constituents
in metabolic syndrome for reduction of obesity, hypertension, fatty liver, hyperlipidaemia or diabetes.
Recently, 0.12% ι-carrageenan has been used in a nasal spray in patients against rhinitis, demonstrating
safety and efficacy [7]. In our previous study, rats fed with κ-carrageenan-producing K. alvarezii showed
normalised body weight and adiposity, lowered systolic blood pressure, improved heart and liver
structure, and lowered plasma lipids, compared to diet-induced obese rats [8].
The aim of the present study was to determine changes in parameters defining cardiovascular and
metabolic health following chronic consumption of S. filiforme, produced through intensive tank-based
cultivation, as a potential commercial source of ι-carrageenan. Firstly, we evaluated the proximate
and elemental composition of S. filiforme. Secondly, a validated diet-induced rat model of metabolic
syndrome that closely mimics the symptoms of human metabolic syndrome was used to measure
cardiovascular and metabolic parameters. We measured systolic blood pressure, diastolic stiffness,
cardiac inflammatory cells and collagen deposition in the heart for cardiovascular effects; plasma liver
enzyme activities, inflammatory cells and fat vacuoles in the liver for liver effects; and body weight,
total cholesterol and triglyceride concentrations, and glucose and insulin tolerance tests for metabolic
effects. Further, we characterised the microbial composition of faecal samples after seaweed treatment,
since functional foods may reverse obesity-induced cardiometabolic changes through alterations in
the gut microbiota [9]. We hypothesised that 5% S. filiforme supplementation for the last 8 weeks will
reverse the changes induced by the high-carbohydrate, high-fat diet to a greater extent than K. alvarezii
due to the additional sulfate group in the disaccharide units of ι-carrageenan. The mechanisms of these
effects could include the actions of ι-carrageenan as a prebiotic in the colon and to prevent infiltration
of inflammatory cells into organs such as the heart and liver.
2. Results
2.1. Preparation of S. filiforme Powder and Analysis
S. filiforme samples were taken from batches grown in the Austral summer during January,
February and March 2018 with an overall average yield of 27 g dry weight/day/m2 (Figure 1A).
This equates to weekly production of 189 g dry weight/m2 of available culture area for intensive
land-based production of the seaweed. In the current study, high-carbohydrate, high-fat diet-fed
rats treated with S. filiforme (HSF) consumed 5% S. filiforme for the last eight weeks (~1.05 g/day).
Using the Reagan-Shaw calculation for rat-to-human scaling, this equates to approximately 6.3 g dry
weight of seaweed/day for humans [10]. For perspective, based on the overall average yield and with
42 m2 of culture area, the University of the Sunshine Coast facility at Bribie Island could provide
continuous seaweed at this dose for 179 people; at this overall yield, 5.7 km2 of culture area could
provide continuous seaweed for the current Australian population. The seaweed powder contained
(in % dry weight): 34.4% carbohydrates (comprising 21.7% total dietary fibre, including 9.6% insoluble
fibre and 12.2% of soluble fibre, almost all as ι-carrageenan), 11.8% protein, 1.4% lipid, 50.8% ash and
1.6% moisture (Table 1). Elemental analysis showed 21.2% C, 3.3% H, 2.6% N, 4.2% S, 18.9% K and
2.7% Na (Table 1). The energy content was 8.7 kJ/g.
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Figure 1. (A) Biomass yields of Sarconema filiforme between January and March 2018. Data show
means ± SEM, n = 20–27 weekly growth measurements from 1000 L outdoor tanks from each month.
(B) Attenuated Total Reflectance-Fourier-Transform Infrared Spectroscopy (ATR-FTIR) transmittance
from 950 to 675 cm−1 of ι-carrageenan (blue line), κ-carrageenan (red line), Kappaphycus alvarezii (green
line) and Sarconema filiforme (orange line). Far left rectangle showing 900–905 cm−1, middle rectangle
showing 820-850 cm−1 and far right rectange showing 800–805 cm−1.
Table 1. Biochemical composition of Sarconema filiforme biomass.
Proximate % dry weight
Metals mg/kg
Carbohydrate 34.4
Protein 11.8 Aluminium 39.3
Lipid 1.4 Antimony 0.1
Ash 50.8 Arsenic 6.2
Moisture 1.6 Barium 0.5
Energy (kJ/g) 8.7 Boron 299
Fibre % dry weight Cadmium 0.1
Total dietary fibre 21.7 Calcium 2150
Insoluble dietary fibre 9.6 Chromium 0.3
Soluble dietary fibre (by difference) 12.2 Cobalt 0.6
Ultimate % dry weight Copper 1.6
Carbon 21.2 Iron 1875
Nitrogen 2.6 Lead 0.2
Hydrogen 3.3 Magnesium 3655
Sulfur 4.2 Manganese 20.3
Amino acids % dry weight Mercury 0.3
Total amino acids 11.8 Molybdenum 0.2
Histidine 0.2 Nickel 0.7
Serine 0.7 Phosphorus 2500
Arginine 1.0 Potassium 189,500
Glycine 0.7 Selenium 0.3
Aspartic acid 1.3 Silver 0.0
Glutamic acid 1.8 Sodium 27,000
Threonine 0.6 Strontium 31.3
Alanine 0.8 Tin 0.1
Proline 0.6 Vanadium 2.4
Lysine 0.6 Zinc 128
Tyrosine 0.3 Fatty acids % dry weight
Methionine 0.2
Valine 0.8 Total fatty acids 1.1
Isoleucine 0.7 C16:0 palmitic 0.4
Leucine 1.0 C20:4ω-6 arachidonic 0.5
Phenylalanine 0.6 C20:5ω-3 eicosapentaenoic 0.1
Values are mean of two sub-samples of blended biomass.
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2.2. ATR-FTIR of S. filiforme and K. alvarezii
The normalised transmission spectra of reference samples of ι-carrageenan and κ-carrageenan are
given with those of S. filiforme and K. alvarezii (Figure 1B). The peak at approximately 800–805 cm−1
is most prominent in ι-carrageenan, which is indicative of 3,6-anhydro-d-galactose 2-sulfate and
the bands between 820 and 850 cm−1 are indicative of galactose 2-sulfate, galactose 4-sulfate and
galactose 2,6-disulfate, which are characteristic of carrageenans. The band at ~800–805 cm−1 is more
prominent in ι-carrageenan and S. filiforme samples. The band at ~905–910 cm−1 is indicative of
anhydro-galactose-2-sulfate which is consistent between ι-carrageenan and S. filiforme samples.
2.3. Physiological and Metabolic Responses
Food intake was higher in corn starch diet-fed rats (C) compared to high-carbohydrate, high-fat
diet-fed rats (H). HSF had lower food intake than H rats (Table 3). The body weight of H rats was
greater than C rats and that of HSF rats was lower than H rats (Figure 2A). Lean mass was unchanged
in all groups. Fat mass measurements were consistent with body weight measurements (Table 3).
Figure 2. (A) Body weight, (B) 12-hour indirect calorimeter data for respiratory exchange ratio and (C)
heat production in corn starch diet-fed rats (C), corn starch diet-fed rats supplemented with Sarconema
filiforme (CSF), high-carbohydrate, high-fat diet-fed rats (H) and high-carbohydrate, high-fat diet-fed
rats supplemented with Sarconema filiforme (HSF). End-point means with unlike superscripts differ (a, b
or c), p < 0.05.
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Table 2. Responses to Sarconema filiforme.
Variables C CSF H HSF
p value
Diet Treatment Interaction
Physiological variables
0 week body weight, g 338 ± 1 338 ± 1 339 ± 1 338 ± 1 0.66 0.66 0.66
8 week body weight, g 371 ± 11b 359 ± 5b 451 ± 15a 442 ± 10a <0.0001 0.31 0.88
16 week body weight, g 405 ± 4c 398 ± 5c 550 ± 15a 498 ± 10b <0.0001 0.004 0.025
16 week lean mass, g 321 ± 9 324 ± 7 309 ± 10 338 ± 12 0.92 0.13 0.22
16 week fat mass, g 59 ± 4c 58 ± 6c 251 ± 30a 151 ± 16b <0.0001 0.004 0.005
8 week lean/fat mass proportion 4.4 ± 0.5b 6.8 ± 0.8a 2.2 ± 0.4c 2.3 ±0.2c <0.0001 0.056 0.08
16 week lean/fat mass proportion 5.5 ± 0.4b 6.0 ± 0.6a 1.3 ± 0.1d 2.5 ± 0.4c <0.0001 0.047 0.93
16 week bone mineral content, g 12.3 ± 0.8c 12.1 ± 0.5c 17.6 ± 0.7a 14.6 ± 0.6b <0.0001 0.021 0.041
16 week bone mineral density, g/cm2 0.180 ± 0.002 0.183 ± 0.004 0.184 ± 0.005 0.184 ± 0.002 0.53 0.70 0.70
Food intake 0-8 weeks, g/day 41.4 ± 0.9a 39.0 ± 1.4a 27.8 ± 0.9b 26.5 ± 1.3b <0.0001 0.21 0.71
Food intake 9-16 weeks, g/day 37.1 ± 0.4a 37.0 ± 1.1a 26.2 ± 0.7b 20.9 ± 0.8c <0.0001 0.012 0.015
Water intake 0-8 weeks, g/day 40.8 ± 4.4a 32.7 ± 2.8b 25.5 ± 0.8c 29.3 ± 2.7b 0.0061 0.51 0.07
Water intake 9-16 weeks, g/day 30.4 ± 3.8b 42.3 ± 1.4a 22.2 ± 0.6c 41.8 ± 2.1a 0.07 <0.0001 0.11
Energy intake 0-8 weeks, kJ/day 468 ± 9b 438 ±16b 593 ± 13a 597 ± 35a <0.0001 0.65 0.55
Energy intake 9-16 weeks, kJ/day 415 ± 4b 407 ± 13b 558 ± 10a 533 ± 17a <0.0001 0.18 0.93
16 week abdominal circumference, cm 20.1 ± 0.4c 19.4 ± 0.1c 23.8 ± 0.5a 21.2 ± 0.3b <0.0001 <0.0001 0.005
Body mass index, g/cm2 0.61 ± 0.02c 0.65 ± 0.01c 0.81 ± 0.03a 0.74 ± 0.02b <0.0001 0.46 0.011
Retroperitoneal fat, mg/mm 216 ± 37c 196 ± 15c 636 ± 67a 423 ± 41b <0.0001 0.007 0.025
Epididymal fat, mg/mm 78 ± 18c 62 ± 9c 191 ± 28a 116 ± 12b <0.0001 0.007 0.07
Omental fat, mg/mm 147 ± 21c 142 ± 12c 333 ± 29a 245 ± 16b <0.0001 0.019 0.035
Visceral adiposity, % 5.1 ± 0.6c 4.8 ± 0.4c 10.0 ± 0.6a 7.8 ± 0.3b <0.0001 0.011 0.048
Liver wet weight, mg/mm 218 ± 7b 231 ± 7b 365 ± 26a 343 ± 16a <0.0001 0.77 0.27
Cardiovascular variables
8 week systolic blood pressure, mmHg 123 ± 4b 122 ± 3b 135 ± 3a 138 ± 2a 0.0001 0.76 0.54
16 week systolic blood pressure, mmHg 128 ± 3b 126 ± 4b 145 ± 4a 132 ± 3b 0.007 0.07 0.18
Left ventricle + septum wet weight, mg/mm 22.6 ± 2.1 22.5 ± 1.0 21.2 ± 2.2 21.5 ± 0.6 0.38 0.94 0.88
Right ventricle, mg/mm 4.1 ± 0.3 3.5 ± 0.3 4.4 ± 0.1 4.3 ± 0.2 0.06 0.22 0.38
Left ventricular diastolic stiffness (κ) 21.2 ± 2.3c 21.7 ± 1.7c 29.6 ± 1.4a 25.6 ± 1.9b 0.022 0.36 0.24
Left ventricle collagen area, % 8.1 ± 2.4c 8.3 ± 1.8c 18.4 ± 1.9a 12.1 ± 1.7b 0.009 0.11 0.11
Left ventricle inflammatory cells, cells/200µm2 7 ± 2c 9 ± 2c 25 ± 3a 16 ± 3b 0.0004 0.1949 0.0520
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Table 3. Responses to Sarconema filiforme.
Variables C CSF H HSF
p Value
Diet Treatment Interaction
Metabolic variables
Plasma total cholesterol, mmol/L 1.59 ± 0.06b 1.44 ± 0.06b 1.73 ± 0.09a 1.51 ± 0.08b 0.18 0.021 0.65
Plasma triglycerides, mmol/L 0.50 ± 0.05b 0.52 ± 0.08b 1.15 ± 0.13a 1.04 ± 0.21a <0.0001 0.73 0.62
Plasma non-esterified fatty acids, mmol/L 0.68 ± 0.12b 0.74 ± 0.24b 2.71 ± 0.29a 1.99 ± 0.59a <0.0001 0.33 0.25
Alanine transaminase, U/L 39 ± 5ab 33 ± 5ab 50 ± 11ab 31 ± 2b 0.55 0.010 0.39
Aspartate transaminase, U/L 138 ± 20ab 125 ± 20b 174 ± 17a 128 ± 13b 0.29 0.011 0.37
Liver inflammatory cells, cells/200µm2 11 ± 2 13 ± 2 30 ± 3a 16 ± 3b 0.0003 0.029 0.005
Liver fat vacuoles area, µm2 12.4 ± 1.2 10.7 ± 1.8 90.6 ± 7.1a 70.4 ± 2.7b <0.0001 0.012 0.029
Oral glucose tolerance test
0 week basal blood glucose, mmol/L 2.6 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 2.5 ± 0.1 0.66 0.66 0.66
0 week area under the curve, mmol/L×min 751 ± 26 650 ± 23 727 ± 23 689 ± 18 0.76 0.007 0.20
8 week basal blood glucose, mmol/L 2.5 ± 0.1b 2.8 ± 0.1b 3.9 ± 0.4a 3.4 ± 0.1a <0.0001 0.60 0.044
8 week 120-min blood glucose, mmol/L 3.6 ± 0.4b 3.6 ± 0.1b 5.2 ± 0.1a 5.1 ± 0.1a <0.0001 0.78 0.78
8 week area under the curve, mmol/L×min 559 ± 34b 538 ± 18b 690 ± 17a 645 ± 12a <0.0001 0.11 0.56
16 week basal blood glucose, mmol/L 2.6 ± 0.1b 2.6 ± 0.2b 3.5 ± 0.3a 3.3 ± 0.2a 0.002 0.67 0.67
16 week 120-min blood glucose, mmol/L 3.6 ± 0.1b 3.8 ± 0.2b 5.8 ± 0.5a 5.0 ± 0.1a <0.0001 0.22 0.043
16 week area under the curve, mmol/L×min 506 ± 22c 547 ± 8b 675 ± 20a 647 ± 18a <0.0001 0.71 0.056
Insulin tolerance test
8 week 120-min blood glucose, mmol/L 2.1 ± 0.7b 2.5 ± 0.5b 3.8 ± 0.5a 4.2 ± 0.4a 0.004 0.47 1.00
8 week area under the curve, mmol/L×min 204 ± 33b 238 ± 36b 349 ± 23a 377 ± 24a 0.0002 0.37 0.93
16 week 120-min blood glucose, mmol/L 3.6 ± 0.4 3.3 ± 1.1 4.3 ± 1.1 3.4 ± 0.3 0.66 0.52 0.74
16 week area under the curve, mmol/L×min 271 ± 64 225 ± 36 396 ± 56 341 ± 19 0.006 0.23 0.91
Values are presented as mean ± SEM, n = 10-12. Means in a row with unlike superscripts differ (a, b or c), p < 0.05. C, corn starch diet-fed rats; CSF, corn starch diet-fed rats supplemented
with Sarconema filiforme; H, high-carbohydrate, high-fat diet-fed rats; HSF, high-carbohydrate, high-fat diet-fed rats supplemented with Sarconema filiforme.
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C rats had higher respiratory exchange ratio compared to H rats, while corn starch diet-fed rats
treated with S. filiforme (CSF) and HSF were the same as H rats (Figure 2B). C rats had lower heat
production than H rats, while CSF was higher than C and HSF was lower than H (Figure 2C). Total
abdominal fat was highest in H rats followed by HSF, CSF and C rats.
After eight weeks, systolic blood pressures of H diet-fed groups (H and HSF) were higher than C
diet-fed groups (C and CSF). Systolic blood pressures in H rats were higher at 16 weeks than in C rats.
HSF rats had decreased systolic blood pressures compared to H control rats. Diastolic stiffness was
higher in H rats compared to C rats. HSF rats showed normalised diastolic stiffness. Left ventricular
with septum wet weights and right ventricular wet weights were unchanged across all groups. Left
ventricles from H rats showed increased infiltration of inflammatory cells and collagen deposition,
whereas these changes were not seen in left ventricles from C rats (Table 3). Infiltration of inflammatory
cells and collagen deposition was normal in hearts from CSF rats and decreased in HSF rats (Figure 3
and Table 3).
Figure 3. Heart inflammation (A–D) using haematoxylin and eosin stain; heart fibrosis (E–H) using
picrosirius red stain; ileum (I–L) and colon (M–P) structure using haematoxylin and eosin stain in
corn starch diet-fed rats (A,E,I,M), corn starch diet-fed rats supplemented with Sarconema filiforme
(B,F,J,N), high-carbohydrate, high-fat diet-fed rats (C,G,K,O) and high-carbohydrate, high-fat diet-fed
rats supplemented with Sarconema filiforme (D,H,L,P). Fibrosis = fb; inflammation = in. Scale bar for
images A-H is 200µm (20×) and for images I-P is 100µm (10×).
Plasma triglyceride concentrations were higher in H and HSF rats compared to C and CSF rats;
plasma total cholesterol concentrations were highest in H rats and lowest in C, CSF and HSF rats; and
plasma non-esterified fatty acids were unchanged across all groups (Table 3). C rats had lower basal
blood glucose concentrations compared to H rats. Intervention with S. filiforme reduced basal blood
glucose concentrations. The blood glucose area under the curve was not different between groups
(Table 3).
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H rats had higher plasma activities of ALT and AST compared to C rats. CSF and HSF rats were
the same as C rats (Table 3). Livers from H rats showed increased fat deposition and infiltration of
inflammatory cells compared to livers from C rats (Table 3 and Figure 4). HSF rats had reduced fat
deposition compared to H rats (Figure 4).
Figure 4. Fat vacuoles (A–D) and inflammation (E–H) using haematoxylin and eosin and liver fat using
oil red O stain (I–L) in corn starch diet-fed rats (A,E,I), corn starch diet-fed rats supplemented with
Sarconema filiforme (B,F,J), high-carbohydrate, high-fat diet-fed rats (C,G,K) and high-carbohydrate,
high-fat diet-fed rats supplemented with Sarconema filiforme (D,H,L). Fat vacuole containing cells = fc;
inflammatory cells = in. Scale bar is 200µm (20×).
2.4. Gut Structure and Microbiota
Histology of ileum and colon did not show any structural abnormalities in the experimental
groups with normal crypt depth, villi length and goblet cells, and less inflammatory cell infiltration
(Figure 3).
The gut microbiota was characterised by a total of 739,069 quality-filtered sequences that were
clustered into 1233 zero-radius operational taxonomic units (zOTUs), which are roughly equivalent
to the taxonomic level of species or strains. The calculated rarefaction curves based on rarefied and
unrarefied data as well as Good’s coverage of 99.67 ± 0.10% showed that the bacterial communities
were almost fully recovered by the surveying effort.
There was no difference in Shannon’s diversity or richness between the four groups (Figure 5). Diet
and seaweed supplement both affected the overall bacterial community structure based on Bray-Curtis
dissimilarity (Figure 6, Table 4; PERMANOVA, both p = 0.0001), and there was an interaction between
the two factors (Figure 6, Table 4; PERMANOVA, p = 0.003). There were pairwise differences between
the C and H groups indicating an effect of basal feed on the bacterial community structure (p = 0.0017).
The addition of S. filiforme changed the bacterial communities (CSF, p = 0.0014; HSF, p = 0.0396).
Bacterial communities in the CSF group were more variable compared to the C group (Figure 6, Table 4;
PERMDISP; p = 0.022).
C rats and CSF rats had lower ratios of Firmicutes to Bacteroidetes (F/B ratio) compared to H
and HSF rats (Figure 7). There was no effect of S. filiforme supplementation on the F/B ratio under
either diet.
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Figure 5. (A) Shannon diversity and (B) richness of faecal samples. C, corn starch diet-fed rats; CSF,
corn starch diet-fed rats supplemented with Sarconema filiforme; H, high-carbohydrate, high-fat diet-fed
rats; HSF, high-carbohydrate, high-fat diet-fed rats supplemented with Sarconema filiforme.
Figure 6. Multi-disciplinary scaling (MDS) plot of bacterial community structure of faecal samples
from different feeding regimes. C, corn starch diet-fed rats; CSF, corn starch diet-fed rats supplemented
with Sarconema filiforme; H, high-carbohydrate, high-fat diet-fed rats; HSF, high-carbohydrate, high-fat
diet-fed rats supplemented with Sarconema filiforme.
Mar. Drugs 2020, 18, 97 10 of 26
Table 4. PERMANOVAs based on Bray-Curtis similarity measure for square-root transformed
abundances of all rat faecal samples.
PERMANOVA
Source df SS MS Pseudo-F P(perm) Unique perms
Diet 1 9306.2 9306.2 9.3671 0.0001 9912
Treatment 1 2477.6 2477.6 2.4938 0.0001 9860
Diet × treatment 1 1671.4 1671.4 1.6823 0.003 9836
Res 19 18876 993.5
Total 22 32369
PAIR-WISE TESTS
Source t P(perm) Unique perms
C, CSF 1.626 0.0014 462
C, H 2.4472 0.0017 462
C, HSF 2.544 0.0024 462
CSF, H 2.3327 0.0018 462
CSF, HSF 2.2125 0.0022 461
H, HSF 1.185 0.0396 462
PERMDISP (PAIRWISE COMPARISONS)
Groups t P(perm)
C, CSF 1.7793 0.022
C, H 0.77115 0.65
C, HSF 0.80101 0.60
CSF, H 0.01072 0.99
CSF, HSF 1.6113 0.24
H, HSF 1.139 0.35
p values were calculated using 9,999 permutations under a residual model. C, corn starch diet-fed rats; CSF,
corn starch diet-fed rats supplemented with Sarconema filiforme; H, high-carbohydrate, high-fat diet-fed rats; HSF,
high-carbohydrate, high-fat diet-fed rats supplemented with Sarconema filiforme.
Figure 7. Effect of supplementation of diet (C or H) with Sarconema filiforme on the ratio of Firmicutes
and Bacteroidetes abundances in rat faecal samples. Statistical analysis performed using ANOVA
with Tukey’s post hoc test for multiple comparisons. C, corn starch diet-fed rats; CSF, corn starch
diet-fed rats supplemented with Sarconema filiforme; H, high-carbohydrate, high-fat diet-fed rats; HSF,
high-carbohydrate, high-fat diet-fed rats supplemented with Sarconema filiforme.
2.5. Taxonomic Structure of the Bacterial Communities
The most abundant bacterial classes found in the faecal samples for different treatment groups
were Bacteroidia, Bacilli, Clostridia, Erysipelotrichia and Verrucomicrobia (Figure 8). Other bacterial
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classes, including Actinobacteria, Coriobacteriia, Melainabacteria, Deferribacteres, Saccharimonadia,
Alphaproteobacteria, Deltaproteobacteria, Gammaproteobacteria and Mollicutes, were observed at
lower abundance levels (<1%) in some (but not all) faecal samples.
Figure 8. Taxonomic profiles of bacterial communities shown at the class level of all faecal samples.
C, corn starch diet-fed rats; CSF, corn starch diet-fed rats supplemented with Sarconema filiforme;
H, high-carbohydrate, high-fat diet-fed rats; and HSF, high-carbohydrate, high-fat diet-fed rats
supplemented with Sarconema filiforme.
The relative abundance of bacteria from the class Bacteroidia was reduced in H rats (15.03% to
17.07%) compared to C rats (29.98% to 32.68%) (p < 0.001). An increase in the relative abundance of
bacteria from class Bacilli was observed in CSF, H and HSF rats (2.01% to 2.89%) compared to the C
rats (0.58%; p > 0.05). A higher abundance of bacteria from the class Clostridia was observed for H rats
(66.51% to 68.76%) compared to C rats (43.47% to 44.59%) (p < 0.0001) (Figure 8). An increase in the
relative abundance of bacteria from the class Verrucomicrobiae and Erysipelotrichia was observed in C
rats (Verrucomicrobiae: 10.74% to 13.92%; Erysipelotrichia: 6.17% to 9.30%) (p > 0.05) compared to H
rats (Verrucomicrobiae: 8.83% to 9%; Erysipelotrichia: 3.86% to 4.33%) (p > 0.05; Figure 8).
Analysis of the bacterial community structure at the family level showed that Bacteroidaceae
(class Bacteriodia), Muribaculaceae (class Bacteriodia), Prevotellaceae (class Bacteroidia),
Lactobacillaceae (class Bacilli), Clostridiaceae 1 (class Clostridia), Lachnospiraceae (class Clostridia),
Peptostreptococcaceae (class Clostridia), Ruminococcaceae (class Clostridia), Erysipelotrichaceae (class
Erysipelotrichia) and Akkermansiacaeae (class Verrucomicrobia) were most dominant in the faecal
samples (Figure 9). The relative abundance of bacteria from the family Ruminococcaceae was reduced
for H rats (8.83% to 9%) compared to C rats (10.74% to 13.92%) (p > 0.05). A high abundance of
bacteria from the family Lachnospiraceae was detected in H rats and HSF rats (36.37% to 39.43%,
p < 0.0001) compared to C rats (15.17% to 15.26%). In contrast, the abundance of bacteria from the family
Muribaculaceae was reduced in H rats (9.16% to 10.28%) compared to C rats (21.27% to 22.77%, p < 0.05)
(Figure 9). Moreover, lower abundance of bacteria from the family Lactobacillaceae was observed for C
rats (0.16%) compared to CSF, H and HSF (1.56% to 2.49%) (p > 0.05).
Analysis of the bacterial community structure at the genus level showed that Bacteroides
(family Bacteroidaceae), unclassified Muribaculaeceae, Clostridium sensu stricto 1 (family Clostridiaceae),
Lachnospiraceae NK4A136 group (family Lachnospiraceae), Roseburia (family Lachnospiraceae), Ruminococcus
1 (family Ruminococcaceae), unclassified Ruminococcaceae, Turicibacter (family Erysipelotrichaceae) and
Akkermansia (family Akkermansiaceae) were most dominant in the faecal samples (Figure 10).
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Figure 9. Taxonomic profiles of bacterial communities shown at the family level of all faecal samples.
C, corn starch diet-fed rats; CSF, corn starch diet-fed rats supplemented with Sarconema filiforme; H,
high-carbohydrate, high-fat diet-fed rats; HSF, high-carbohydrate, high-fat diet-fed rats supplemented
with Sarconema filiforme.
Figure 10. Taxonomic profiles of bacterial communities shown at the genus level of all faecal samples.
C, corn starch diet-fed rats; CSF, corn starch diet-fed rats supplemented with Sarconema filiforme; H,
high-carbohydrate, high-fat diet-fed rats; HSF, high-carbohydrate, high-fat diet-fed rats supplemented
with Sarconema filiforme.
2.6. Multivariate Analysis of Physiological Data
A total of 23 physiological parameters were assessed and included in the analysis below (body
weight, fat mass, lean mass, water intake, food intake, energy intake, feed efficiency, left ventricle with
septum wet weight, right ventricle wet weight, retroperitoneal fat, omental fat, epididymal fat, total
abdominal fat, liver wet weight, kidney wet weight, spleen wet weight, plasma non-esterified fatty
acids, plasma triglycerides, systolic blood pressure, oral glucose tolerance area under the curve, oral
glucose tolerance 120 min blood glucose concentrations, plasma aspartate transaminase activity and
plasma alanine transaminase activity) for rats fed with the C and H diets and supplemented with
S. filiforme (Table 5).
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Table 5. PERMANOVAs based on Euclidean distance matrix for physiological data of all rat faecal samples.
PERMANOVA
Source df SS MS Pseudo-F P(perm) Unique perms
Diet 1 4081700 4081700 53.366 0.0001 9924
Treatment 1 435050 435050 5.6882 0.0154 9942
Diet × treatment 1 408770 408770 5.3446 0.0187 9939
Res 20 1529700 76484
Total 23 6455200
PAIR-WISE TESTS
Source t P(perm) Unique perms
C, CSF 0.6848 0.82 462
C, H 5.6852 0.0018 461
C, HSF 4.4192 0.0024 462
CSF, H 5.8892 0.0021 462
CSF, HSF 4.7191 0.0023 462
H, HSF 2.5161 0.0268 462
PERMDISP (PAIRWISE COMPARISONS)
Groups t P(perm)
C, CSF 1.5351 0.23
C, H 1.9906 0.11
C, HSF 1.4159 0.20
CSF, H 2.4448 0.0398
CSF, HSF 2.2429 0.0139
H, HSF 1.0507 0.29
p values were calculated using 9999 permutations under a residual model. C, corn starch diet-fed rats; CSF,
corn starch diet-fed rats supplemented with Sarconema filiforme; H, high-carbohydrate, high-fat diet-fed rats; HSF,
high-carbohydrate, high-fat diet-fed rats supplemented with Sarconema filiforme.
Distance-based multivariate analysis showed that treatments have distinct responses on the
physiological parameters. Diet and supplement affected the rats’ physiological variables (Figure 11,
Table 5; PERMANOVA; p = 0.0001 and p = 0.0154, respectively) and there was an interaction between
the two factors (Figure 11, Table 5; PERMANOVA, p = 0.0187).
Figure 11. Non-metric multi-disciplinary scaling (nMDS) plot of physiological data from all
physiological parameters measured after 16 weeks of feeding. C, corn starch diet-fed rats; CSF,
corn starch diet-fed rats supplemented with Sarconema filiforme; H, high-carbohydrate, high-fat diet-fed
rats; HSF, high-carbohydrate, high-fat diet-fed rats supplemented with Sarconema filiforme.
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There was statistical support for differences between C and H rats without S. filiforme (p = 0.0018,
Table 5) indicating an effect of basal diet on the overall physiological variables. There was also an effect
for the addition of S. filiforme to the H diet (p = 0.0268; Figure 11, Table 5), however supplementation
had no effect for C diet. Rat physiological variables in H and HSF rats were more variable between
replicates compared to the CSF rats (Figure 11, Table 5; PERMDISP; p = 0.0398, p = 0.0139, respectively).
2.7. Differentially Abundant zOTUs under Different Feeding Treatments
Multivariate analysis of individual zOTUs using the R package Mvabund revealed that diet and
supplement, as well as the interaction between diet and supplement had a significant effect on the
bacterial community structure in the faecal samples (Table 6). At the zOTU level, diet had a stronger
effect than supplementation with S. filiforme on the bacterial community structure by affecting the
abundance of 77 zOTUs (6.24% of total zOTUs) (Table 6).
Table 6. Summary of statistical tests on differential zOTU abundance.
Global Test (GLMs) by Mvabund
Diet: p < 0.0001
Treatment: p = 0.003
Diet × Treatment: p < 0.007
Univariate Analysis by Mvabund (p < 0.05)
Factor Number of differentiallyabundant OTUs
% of total
number of OTUs
Diet 77 6.24%
Treatment 35 0.32%
Total (unique zOTUs affected by one or more factors) 81 6.57%
zOTUs belonging to the phylum Firmicutes (families: Lachnospiraceae, Peptococcaceae and
Ruminococcaceae; genus: Acetatifactor, Anaerostipes, Blautia, GCA-900066575, Lachnoclostridium,
Lachnospiraceae FCS020 group, Lachnospiraceae NK4A136 group, Lachnospiraceae UCG-006, Lachnospiraceae
UCG-008, Roseburia, unclassified Lachnospiraceae, unclassified Peptococcaceae, Butyricicoccus,
Ruminiclostridium, Ruminiclostridium 9 and unclassified Ruminococcaceae) were reduced in abundance
or absent in C and CSF rats compared to H and HSF rats, respectively, while zOTUs belonging
to the family Ruminococcaceae (genus: Ruminococcaceae NK4A214 group) were enriched in C and
CSF rats compared to H and HSF rats (Table 7). Bacteria belonging to the phylum Actinobacteria
(families: Bifidobacteriaceae and Eggerthellaceae; genus: Bifidobacterium and Enterorhabdus) and the
phylum Bacteroidetes (families: Bacteroidaceae, Muribaculaceae and Prevotellaceae; genus: Bacteroides,
unclassified Muribaculaceae and Prevotellaceae UCG-001) were either reduced or absent in H and HSF
rats (Table 7).
Table 7. Relative abundance of zOTUs affected by diet (ANOVA with p adjusted <0.05) between C,
CSF, H and HSF rats.
OTU_ID C (%) CSF (%) H (%) HSF (%) Phylum Family Genus
Zotu42 0.62 0.31 0.00 0.02 Actinobacteria Bifidobacteriaceae Bifidobacterium
Zotu80 0.29 0.22 0.00 0.00 Actinobacteria Bifidobacteriaceae Bifidobacterium
Zotu168 0.12 0.09 0.01 0.01 Actinobacteria Eggerthellaceae Enterorhabdus
Zotu20 0.95 0.90 0.02 0.08 Bacteroidetes Bacteroidaceae Bacteroides
Zotu21 1.11 0.73 0.16 0.09 Bacteroidetes Muribaculaceae unclassified
Zotu27 1.05 0.37 0.05 0.06 Bacteroidetes Muribaculaceae unclassified
Zotu79 0.40 0.13 0.02 0.01 Bacteroidetes Muribaculaceae unclassified
Zotu541 0.02 0.05 0.00 0.00 Bacteroidetes Muribaculaceae unclassified
Zotu857 0.08 0.04 0.00 0.00 Bacteroidetes Muribaculaceae unclassified
Zotu978 0.12 0.11 0.01 0.03 Bacteroidetes Muribaculaceae unclassified
Zotu1036 0.05 0.02 0.00 0.00 Bacteroidetes Muribaculaceae unclassified
Zotu1144 0.12 0.04 0.00 0.01 Bacteroidetes Muribaculaceae unclassified
Zotu10 2.06 2.28 0.28 0.19 Bacteroidetes Prevotellaceae Prevotellaceae UCG-001
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Table 7. Cont.
OTU_ID C (%) CSF (%) H (%) HSF (%) Phylum Family Genus
Zotu916 0.00 0.00 0.02 0.02 Firmicutes Lachnospiraceae Acetatifactor
Zotu77 0.04 0.05 0.30 0.54 Firmicutes Lachnospiraceae Anaerostipes
Zotu244 0.01 0.00 0.07 0.11 Firmicutes Lachnospiraceae Blautia
Zotu49 0.01 0.02 0.81 0.43 Firmicutes Lachnospiraceae GCA-900066575
Zotu76 0.03 0.03 0.64 0.20 Firmicutes Lachnospiraceae Lachnoclostridium
Zotu856 0.00 0.00 0.03 0.02 Firmicutes Lachnospiraceae Lachnospiraceae FCS020 group
Zotu1061 0.00 0.00 0.03 0.03 Firmicutes Lachnospiraceae Lachnospiraceae FCS020 group
Zotu37 0.01 0.01 0.81 1.19 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu100 0.36 0.14 0.00 0.02 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu123 0.00 0.00 0.20 0.40 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu182 0.00 0.00 0.18 0.23 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu201 0.01 0.01 0.18 0.13 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu544 0.00 0.00 0.13 0.09 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu561 0.00 0.00 0.06 0.03 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu658 0.00 0.00 0.48 0.54 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu762 0.00 0.00 0.02 0.04 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu847 0.00 0.00 0.03 0.02 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu966 0.00 0.00 0.08 0.10 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu1157 0.00 0.01 0.12 0.35 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group
Zotu26 0.00 0.00 1.65 1.27 Firmicutes Lachnospiraceae Lachnospiraceae UGC-006
Zotu110 0.01 0.02 0.49 0.25 Firmicutes Lachnospiraceae Lachnospiraceae UGC-008
Zotu35 0.01 0.01 1.69 0.32 Firmicutes Lachnospiraceae Roseburia
Zotu556 0.00 0.00 0.02 0.04 Firmicutes Lachnospiraceae Roseburia
Zotu582 0.00 0.00 0.02 0.05 Firmicutes Lachnospiraceae Roseburia
Zotu604 0.00 0.00 0.01 0.05 Firmicutes Lachnospiraceae Roseburia
Zotu625 0.00 0.00 0.01 0.03 Firmicutes Lachnospiraceae Roseburia
Zotu634 0.00 0.00 0.01 0.05 Firmicutes Lachnospiraceae Roseburia
Zotu25 0.00 0.00 1.10 0.83 Firmicutes Lachnospiraceae unclassified
Zotu52 0.09 0.04 0.48 0.48 Firmicutes Lachnospiraceae unclassified
Zotu73 0.02 0.00 0.24 0.44 Firmicutes Lachnospiraceae unclassified
Zotu101 0.00 0.00 0.28 0.24 Firmicutes Lachnospiraceae unclassified
Zotu174 0.00 0.00 0.13 0.32 Firmicutes Lachnospiraceae unclassified
Zotu197 0.00 0.00 0.46 0.05 Firmicutes Lachnospiraceae unclassified
Zotu198 0.02 0.02 0.27 0.32 Firmicutes Lachnospiraceae unclassified
Zotu221 0.00 0.00 0.14 0.09 Firmicutes Lachnospiraceae unclassified
Zotu226 0.00 0.00 0.15 0.22 Firmicutes Lachnospiraceae unclassified
Zotu277 0.00 0.00 0.20 0.04 Firmicutes Lachnospiraceae unclassified
Zotu293 0.00 0.00 0.04 0.18 Firmicutes Lachnospiraceae unclassified
Zotu516 0.00 0.00 0.07 0.06 Firmicutes Lachnospiraceae unclassified
Zotu528 0.00 0.00 0.05 0.03 Firmicutes Lachnospiraceae unclassified
Zotu530 0.00 0.00 0.06 0.05 Firmicutes Lachnospiraceae unclassified
Zotu590 0.00 0.00 0.05 0.04 Firmicutes Lachnospiraceae unclassified
Zotu757 0.00 0.00 0.01 0.04 Firmicutes Lachnospiraceae unclassified
Zotu891 0.00 0.00 0.02 0.02 Firmicutes Lachnospiraceae unclassified
Zotu937 0.00 0.00 0.07 0.26 Firmicutes Lachnospiraceae unclassified
Zotu988 0.00 0.00 0.01 0.01 Firmicutes Lachnospiraceae unclassified
Zotu1043 0.01 0.02 0.23 0.17 Firmicutes Lachnospiraceae unclassified
Zotu1161 0.00 0.00 0.09 0.04 Firmicutes Lachnospiraceae unclassified
Zotu1200 0.00 0.01 0.33 0.16 Firmicutes Lachnospiraceae unclassified
Zotu247 0.00 0.00 0.13 0.04 Firmicutes Peptococcaceae unclassified
Zotu398 0.05 0.04 0.00 0.00 Firmicutes Peptococcaceae unclassified
Zotu384 0.00 0.00 0.10 0.02 Firmicutes Ruminococcaceae Butyricicoccus
Zotu279 0.00 0.00 0.07 0.08 Firmicutes Ruminococcaceae Ruminiclostridium
Zotu614 0.00 0.00 0.02 0.04 Firmicutes Ruminococcaceae Ruminiclostridium
Zotu958 0.00 0.00 0.01 0.01 Firmicutes Ruminococcaceae Ruminiclostridium
Zotu63 0.00 0.00 0.51 0.30 Firmicutes Ruminococcaceae Ruminiclostridium 9
Zotu133 0.01 0.00 0.15 0.23 Firmicutes Ruminococcaceae Ruminiclostridium 9
Zotu135 0.00 0.00 0.17 0.21 Firmicutes Ruminococcaceae Ruminiclostridium 9
Zotu643 0.01 0.04 0.00 0.00 Firmicutes Ruminococcaceae Ruminiclostridium 9
Zotu38 0.93 0.21 0.00 0.00 Firmicutes Ruminococcaceae Ruminiclostridium NK4A214 group
Zotu218 0.08 0.07 0.01 0.01 Firmicutes Ruminococcaceae Ruminiclostridium NK4A214 group
Zotu50 0.01 0.04 0.50 0.38 Firmicutes Ruminococcaceae unclassified
Zotu62 0.02 0.00 0.46 0.43 Firmicutes Ruminococcaceae unclassified
Zotu275 0.00 0.00 0.06 0.12 Firmicutes Ruminococcaceae unclassified
Differential abundance analysis was performed using Mvabund. C, corn starch diet-fed rats; CSF, corn starch diet-fed
rats supplemented with Sarconema filiforme; H, high-carbohydrate, high-fat diet-fed rats; HSF, high-carbohydrate,
high-fat diet-fed rats supplemented with Sarconema filiforme.
A total of four zOTUs (0.32% of total zOTUs) belonging mostly to phylum Firmicutes were
significantly affected by S. filiforme supplementation (Table 8). One zOTU belonging to the phylum
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Bacteroidetes was enriched in C and H rats, while bacteria belonging to the phylum Firmicutes and
family Ruminococcaceae (genus: Ruminococcaceae UCG-014) and the phylum Proteobacteria and family
Desulfovibrionaceae (genus: Bilophila) were absent in C and H rats (Table 8).
Table 8. Relative abundance of zOTUs affected by treatment (ANOVA with p adjusted <0.05) between
C, CSF, H and HSF rats.
OTU_ID C (%) CSF (%) H (%) HSF (%) Phylum Family Genus
Zotu15 0.72 0.00 3.02 0.00 Bacteroidetes Muribaculaceae unclassified
Zotu232 0.00 0.06 0.00 0.13 Firmicutes Ruminococcaceae Ruminococcaceae UCG-014
Zotu595 0.00 0.04 0.00 0.01 Firmicutes Ruminococcaceae Ruminococcaceae UCG-014
Zotu40 0.00 0.70 0.00 0.43 Proteobacteria Desulfovibrionaceae Bilophila
Differential abundance analysis was performed using Mvabund. C, corn starch diet-fed rats; CSF, corn starch diet-fed
rats supplemented with Sarconema filiforme; H, high-carbohydrate, high-fat diet-fed rats; HSF, high-carbohydrate,
high-fat diet-fed rats supplemented with Sarconema filiforme.
2.8. Correlation of Microbiota and Physiological Parameters
Combined analysis of bacterial community structure and physiological parameters was performed.
The Mantel test revealed that overall the bacterial community structure and the physiological data
are correlated (Mantel statistic r = 0.2177; p = 0.0071). Table 9 and Figure 12 show how individual
physiological parameters contribute to the differences in bacterial community structure between
treatments (function envfit – vegan R package).
Table 9. Correlation between bacterial community structure and physiological parameters (p < 0.05).
Physiological Variables R2 p-Value
Epididymal fat 0.59 0.001
Water intake 0.58 0.002
Total abdominal fat 0.56 0.001
Retroperitoneal fat 0.54 0.002
Systolic blood pressure 0.53 0.001
Left ventricle and septum wet weight 0.47 0.001
Fat mass 0.46 0.001
Kidneys wet weight 0.44 0.002
Omental fat 0.40 0.007
Body weight 0.39 0.004
Liver wet weight 0.37 0.011
Right ventricle wet weight 0.33 0.003
Oral glucose tolerance area under the curve 0.33 0.025
Oral glucose tolerance 120-minute blood glucose 0.29 0.027
Food intake 0.25 0.033
Physiological variables were further correlated with individual zOTUs (Table 10). A total of
44 zOTUs were found to be statistically correlated with at least one of the physiological parameters
(p < 0.05). Of the zOTUs, 33 out of 44 belonged to the phylum Firmicutes, nine zOTUs to the phylum
Bacteroidetes, one zOTU to the phylum Proteobacteria and one zOTU to the phylum Actinobacteria.
Food intake (7 of 44 zOTUs or 15.91%) was inversely correlated with the relative abundance of the
selected zOTU. In contrast, water intake (16 of 44 zOTUs or 36.36%), epididymal fat (4 of 44 zOTUs or
9.1%), left ventricle and septum weight (3 of 44 zOTUs or 6.82%), oral glucose tolerance (3 of 44 zOTUs
or 6.82%), systolic blood pressure (3 of 44 zOTUs or 6.82%), liver wet weight (3 of 44 zOTUs or 6.82%)
and total abdominal fat (2 of 44 zOTUs or 4.55%) were positively correlated with the selected zOTUs
(Table 10).
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Figure 12. Correlation between bacterial community structure (points) and environmental variables
(arrows). C, corn starch diet-fed rats; CSF, corn starch diet-fed rats supplemented with Sarconema
filiforme; H, high-carbohydrate, high-fat diet-fed rats; HSF, high-carbohydrate, high-fat diet-fed rats
supplemented with Sarconema filiforme.
Table 10. Taxonomic assignments of the zOTUs strongly correlated with physiological parameters.
OTU_ID Phylum Family Genus Correlation with PhysiologicalParameters
Zotu42 Actinobacteria Bifidobacteriaceae Bifidobacterium Water intake (−)
Zotu20 Bacteroidetes Bacteroidaceae Bacteroides Left ventricle and septum wetweight (+), water intake (−)
Zotu1036 Bacteroidetes Muribaculaceae unclassified Water intake (−)
Zotu1144 Bacteroidetes Muribaculaceae unclassified Water intake (−)
Zotu21 Bacteroidetes Muribaculaceae unclassified Water intake (−)
Zotu27 Bacteroidetes Muribaculaceae unclassified Water intake (−)
Zotu541 Bacteroidetes Muribaculaceae unclassified Epididymal fat (+)
Zotu79 Bacteroidetes Muribaculaceae unclassified Water intake (−)
Zotu857 Bacteroidetes Muribaculaceae unclassified Water intake (−)
Zotu10 Bacteroidetes Prevotellaceae Prevotellaceae UCG-001 Left ventricle and septum wetweight (+), water intake (−)
Zotu77 Firmicutes Lachnospiraceae Anaerostipes Food intake (−), water intake (+)
Zotu244 Firmicutes Lachnospiraceae Blautia Water intake (+)
Zotu856 Firmicutes Lachnospiraceae Lachnospiraceae FCS020 group Water intake (+)
Zotu100 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group Water intake (−)
Zotu37 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group Left ventricle and septum wetweight (−)
Zotu762 Firmicutes Lachnospiraceae Lachnospiraceae NK4A136 group Water intake (+)
Zotu556 Firmicutes Lachnospiraceae Roseburia Food intake (−), water intake (+)
Zotu582 Firmicutes Lachnospiraceae Roseburia Food intake (−)
Zotu604 Firmicutes Lachnospiraceae Roseburia Food intake (−)
Zotu625 Firmicutes Lachnospiraceae Roseburia Water intake (+)
Zotu634 Firmicutes Lachnospiraceae Roseburia Food intake (−)
Zotu101 Firmicutes Lachnospiraceae unclassified Water intake (−)
Zotu174 Firmicutes Lachnospiraceae unclassified Food intake (−)
Zotu198 Firmicutes Lachnospiraceae unclassified Left ventricle and septum wetweight (−)
Zotu25 Firmicutes Lachnospiraceae unclassified Water intake (+)
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Table 10. Cont.
OTU_ID Phylum Family Genus Correlation with PhysiologicalParameters
Zotu516 Firmicutes Lachnospiraceae unclassified Water intake (+)
Zotu52 Firmicutes Lachnospiraceae unclassified Left ventricle and septum wetweight (−)
Zotu530 Firmicutes Lachnospiraceae unclassified Water intake (+)
Zotu590 Firmicutes Lachnospiraceae unclassified Left ventricle and septum wetweight (−)
Zotu73 Firmicutes Lachnospiraceae unclassified Water intake (+)
Zotu757 Firmicutes Lachnospiraceae unclassified Food intake (−)
Zotu891 Firmicutes Lachnospiraceae unclassified Water intake (+)
Zotu988 Firmicutes Lachnospiraceae unclassified Water intake (+)
Zotu398 Firmicutes Peptococcaceae unclassified Water intake (−)
Zotu279 Firmicutes Ruminococcaceae Ruminiclostridium Left ventricle and septum wetweight (−), water intake (+)
Zotu614 Firmicutes Ruminococcaceae Ruminiclostridium Left ventricle and septum wetweight (−)
Zotu643 Firmicutes Ruminococcaceae Ruminiclostridium 9
Body weight (+), retroperitoneal
fat (+), epididymal fat (+),
omental fat (+), Total abdominal
fat (+), fat mass (+), Liver wet
weight (+), Left ventricle and
septum wet weight (+), oral
glucose tolerance 120-minute
blood glucose (+), systolic blood
pressure (+), water intake (−)
Zotu133 Firmicutes Ruminococcaceae Ruminiclostridium 9 Water intake (+)
Zotu135 Firmicutes Ruminococcaceae Ruminiclostridium 9 Water intake (+)
Zotu63 Firmicutes Ruminococcaceae Ruminiclostridium 9 Left ventricle and septum wetweight (−)
Zotu595 Firmicutes Ruminococcaceae Ruminococcaceae UCG-014
Epididymal fat (+),
retroperitoneal fat (+), right
ventricle wet weight (+), systolic
blood pressure (+)
Zotu232 Firmicutes Ruminococcaceae Ruminococcaceae UCG-014 Liver wet weight (+)
Zotu62 Firmicutes Ruminococcaceae unclassified Left ventricle and septum wetweight (−), water intake (+)
Zotu40 Proteobacteria Desulfovibrionaceae Bilophila
Epididymal fat (+), omental fat
(+), retroperitoneal fat (+), total
abdominal fat (+), kidney wet
weight (+), liver wet weight (+),
oral glucose tolerance
120-minute blood glucose (+),
oral glucose tolerance area
under the curve (+), systolic
blood pressure (+)
Differential abundance analysis was performed using Mvabund. This table includes the physiological parameters
strongly correlated (P < 0.05) with the bacterial community and incorporates zOTUs that interact with at least 1 of
these parameters. Plus sign (+) indicates positive correlations, while minus sign (−) indicates negative correlations.
The relative abundances of zOTUs belonging to the phylum Firmicutes and the families
Lachnospiraceae (genus: Anaerostipes, Blautia, Lachnospiraceae FCS020 group, Lachnospiraceae NK4A136
group, Roseburia, unclassified Lachnospiraceae: zOTU77, zOTU244, zOTU856, zOTU762, zOTU37,
zOTU556, zOTU582, 174, zOTU25, zOTU198, zOTU52 and zOTU590) and Ruminococcaceae (genus:
Rumiclostridium and Rumiclostridium 9: zOTU279, zOTU614, zOTU133, zOTU135 and zOTU63) were
inversely correlated with food intake and left ventricle and septum weight and positively correlated
with water intake. While bacteria belonging to the phylum Firmicutes and family Peptococcaceae
(zOTU398) were negatively correlated to water intake, bacteria belonging to the family Ruminococcaceae
UCG-014 (zOTU595, zOTU232) were positively correlated to several physiological parameters including
epididymal fat, retroperitoneal fat, right ventricle weight, systolic blood pressure and liver wet weight.
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The relative abundances of bacteria belonging to the phylum Actinobacteria and family
Bifidobacteriaceae; the phylum Bacteroidetes and families Bacteroidaceae, Muribaculaceae and
Prevotellaceae (for example: zOTU42, zOTU1036, zOTU1144, zOTU21, zOTU27, zOTU79 and
zOTU857) were negatively correlated to water intake. Several zOTUs belonging to the phylum
Bacteroidetes and families Bacteroidaceae and Prevotellaceae were also positively correlated with left
ventricle and septum weight (zOTU20 and zOTU10). The relative abundance of bacteria belonging to
the phylum Proteobacteria and family Desulfovibrionaceae was positively correlated to epididymal fat,
kidney weight, liver weight, oral glucose tolerance 120-minute blood glucose, oral glucose tolerance
area under the curve, omental fat, retroperitoneal fat, systolic blood pressure and total abdominal fat
(zOTU40).
3. Discussion
This project demonstrates that local Australian cultivation of S. filiforme produced significant
and reliable yields of biomass in intensive tank-based culture, which can therefore potentially be
a source of commercial quantities of ι-carrageenan. Australia has unique and untapped seaweed
resources [11]; however, as of 2014, the Australian seaweed industry was small and only based on
the harvest of stormcast kelp for alginate and fertiliser and on introduced species of Undaria for the
extraction of bioactive compounds [12]. However, indigenous species such as S. filiforme could supply
high-value fresh and dried foods as well as compounds for the nutraceutical and pharmaceutical
markets. Consuming locally grown foods is considered important, because it reduces transport to
markets and environmental impact to decrease CO2 emissions. In addition, local production supports
the local economy as evidenced by the successful commercial cultivation of the red seaweed, K. alvarezii,
in countries such as the Philippines and Indonesia as a main source of carrageenan for the food industry
for more than 40 years [13].
Further, we show that whole dried S. filiforme may be useful in reversing metabolic syndrome.
Metabolic syndrome including abdominal obesity, hypertension, hyperglycaemia, fatty liver and
inflammation increases the risk of cardiovascular disease and diabetes; this syndrome is mimicked
by a diet high in simple sugars, saturated and trans fats in rats [14]. This validated dietary model of
human metabolic syndrome has been previously reported to show reversal of changes by interventions
with seaweeds [15,16]. The major findings from the current reversal study were that S. filiforme
decreased metabolic, cardiovascular and liver changes by 9-40% in obese rats fed a high-carbohydrate,
high-fat diet, including some variables that were effectively reversed including liver enzymes and
systolic blood pressure. These results are consistent with our previous study where K. alvarezii
containing κ-carrageenan was used in a prevention protocol [8]. The soluble fibre content, which
also approximates the carrageenan content, was ~35% in K. alvarezii and ~12% in S. filiforme, giving
a soluble fibre content in the rat diets of around 1.7% and 0.5%, respectively. This was markedly less
than the upper limit of 5% to avoid any safety risks, as recommended by the Scientific Committee
on Food of the European Commission, for carrageenans below a molecular weight limit of 50 kDa
when used as a food additive [17]. Although carrageenans have been used in subcutaneous injections
to induce rat paw oedema as a model of inflammation [18], there have been dietary studies with no
adverse effects using 5% ι-carrageenan prepared from E. denticulatum (previously E. spinosum) [19,20],
although systemic administration of carrageenan increased biliary antibody titre, which is suggestive
of bacterial intrusion [20,21]. In the literature, there are conflicting reports on the effects of carrageenans
on the gastrointestinal tract, although the confusion may be in part due to inconsistent nomenclature.
Degraded carrageenans have been incorrectly referred to as poligeenans, which are not produced
biologically. Poligeenans are produced in the laboratory or commercially by subjecting carrageenan
to very low pH at 0.9–1.3 and non-physiological temperatures of >80◦C for several hours [22].
As carrageenans are not absorbed from the gastrointestinal tract after oral administration, studies
using systemic administration are not appropriate for a risk assessment of carrageenans when used as
food products in subjects without gastrointestinal pathology [23]. However, oral studies can determine
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local gastrointestinal risk; the current study shows no histopathological impact on the ileum or colon in
H rats compared to HSF rats, consistent with the previous study on oral administration of K. alvarezii
containing κ-carrageenan [8].
Traditionally, people in East Asian countries, such as Korea, Japan and China, consume more
seaweeds as food and ingredients of traditional medicine than other populations [24]. The average
intake of seaweeds in Japan was 14.3 g (wet weight)/day [25]. In the current study, the dose in rats
equates to approximately 6.3 g of seaweed/day for humans [10]. Therefore, it is realistic that this
quantity can be consumed as a single seaweed such as S. filiforme in the usual diet to translate its health
benefits. Further, production of therapeutic amounts of this seaweed requires a small area, as the 42 m2
research facility of the University of the Sunshine Coast could provide enough seaweed for 179 people
to be treated continuously, based on measured seaweed growth rates. This is markedly more efficient
usage of space than with other sources of dietary fibre such as cereals; as an example, the average
cereal yield in the USA was 828 g/m2/year in 2017 [26] compared to the average yield of seaweed at the
University of the Sunshine Coast of around 189 g/m2/week (or around 10 kg/m2/year). Scaling up to
produce commercial amounts of seaweed is therefore realistic.
Dietary fibre is classified as either soluble (non-cellulosic, polysaccharides, oligosaccharides,
pectins, β-glucans and gums) or insoluble (cellulose, hemicellulose and lignin). The major physiological
effects of soluble fibre are delayed gastric emptying, regulation of blood glucose levels and lowered
serum cholesterol concentrations, due to increasing gut content viscosity and colonic fermentation.
In contrast, the major effects of insoluble fibre are shortened gut transit time and improved laxation,
both due to faecal bulking capacity and support for the growth of intestinal bacteria due to colonic
fermentation [27]. S. filiforme contains about 22% fibre, which equates to 1.3 g of fibre per day if the
human dose is 6.3 g/day, based on the Reagan-Shaw rat to human scaling equation [10]. The American
Dietetic Association recommended a daily dietary fibre intake of 25 g for adult females and 38 g for
adult males [28]. Therefore, Sarconema at this dose would increase fibre consumption, but alone would
not provide sufficient fibre to meet this recommendation; consequently, other fibre-rich foods such
as fruits, vegetables, beans and grains would be necessary components of the diet. Epidemiological
and clinical studies have demonstrated that dietary fibre intake is inversely related to obesity [29],
type 2 diabetes [30] and cardiovascular disease [31]. The consumption of dietary fibre likely reduces
body fat accumulation due to several factors such as fermentation of the fibre in the colon, stimulating
production of glucagon-like-peptide-1 and peptide YY [32]. These gut hormones increase satiety, which
may lead to decreased meal frequency and size. Consumption of insoluble fibre reduced body weight
and body fat and also normalised fasting glucose and insulin concentrations in overweight and obese
adults [33].
Carrageenans undergo minimal digestion in the stomach and are then fermented by colonic
bacteria [34], hence meeting the definition of prebiotics [35]. Health benefits of prebiotics include
decreased blood pressure and body weight [27,36] similar to the responses from the current study.
Using the same rat model of diet-induced obesity, a prebiotic mixture of inulin and oligofructose
was reported as an effective dietary fibre, reducing body weight, plasma concentrations of free fatty
acids and triglycerides, and systolic blood pressure and attenuating inflammatory cell infiltration in
the heart and liver [37]. Red seaweeds show responses that suggest the biological actions of fibre
as prebiotics. Subjects supplemented with the red seaweed Chondrus crispus showed improved gut
health and immune modulation [38]. Another red seaweed, Mastocarpus stellatus, with 31.7% dietary
fibre reduced triglycerides and total cholesterol concentrations, however, there was no effect on body
weight in healthy Wistar rats [39]. Complex polysaccharides exert their action through a wide range of
mechanisms including selective fermentation, lowering the gut pH, faecal bulking, preventing gut
colonisation by pathogens, controlling putrefactive bacteria, and therefore reducing the host’s exposure
to toxic metabolites [40]. These effects are likely due to dietary fibre increasing short-chain fatty acid
production as these are used as an energy source by selected gut microbiota. Short-chain fatty acids
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decrease the luminal pH, improve calcium and magnesium absorption, reduce potential pathogenic
bacteria and act as an energy source for epithelial cells [41].
4. Materials and Methods
4.1. Sarconema filiforme Source and Analysis
S. filiforme was cultured at the University of the Sunshine Coast seaweed aquaculture facility at
the Bribie Island Research Centre, Woorim, QLD, Australia (27◦04′10′′ S; 153◦12′15′′ E) from January
to March 2018. Production (yield of dry weight/m2/day) was measured through weekly harvests
from up to five 1000 L fibreglass tanks over 13 weeks from cultures initially stocked each week at,
on average, 7 g fresh weight per 1000 L of seawater. Cultures received flow-through seawater with
weekly addition of nutrients (MAF, Manutech, Cavan, SA, Australia). Fresh samples were harvested
each week, dehydrated and a total of 3 kg dried and milled S. filiforme was sub-sampled across the three
months of production and stored in vacuum-sealed bags containing silica desiccant. Compositional
analysis of the seaweed was performed as detailed previously [42,43].
Attenuated Total Reflectance-Fourier-Transform Infrared Spectroscopy (ATR-FTIR) was performed
at Southern Cross University, Lismore, NSW, Australia to determine carrageenan subtypes in S. filiforme
and K. alvarezii as a control and commercial grade ι-carrageenan and κ-carrageenan (Sigma-Aldrich
Australia, Castle Hill, NSW, Australia) as standards. The transmittance spectra were recorded from
2000 to 675 cm−1 [44].
4.2. Rats and Diets
All experimental protocols were approved by the Animal Ethics Committee of the University of
Southern Queensland under the guidelines of the National Health and Medical Research Council of
Australia. Male Wistar rats (8–9 weeks old; 338 ± 1 g, n = 48) were obtained from the Animal Resource
Centre, Murdoch, WA, Australia. Rats were individually housed in a temperature-controlled (21 ±
2 ◦C), 12-hour light/dark conditions with free access to food and water. Rats were randomly distributed
into four groups, each of 12 rats. Two groups were fed either corn starch or high-carbohydrate, high-fat
diets (C and H, respectively) [14] for a full 16 weeks. The other two groups received C and H diets for
the first eight weeks and then received 5% S. filiforme in the diet for the last eight weeks (CSF and HSF,
respectively). The C diet contained 570 g of cornstarch, 155 g of powdered rat food (Specialty Feeds,
Glen Forest, WA, Australia), 25 g of Hubble, Mendel and Wakeman salt mixture (MP Biomedicals,
Seven Hills, NSW, Australia), and 250 g of water per kilogram of diet. The H diet contained 175 g
of fructose, 395 g of sweetened condensed milk, 200 g of beef tallow, 155 g of powdered rat food (all
obtained from local food suppliers and supermarkets), 25 g of Hubble, Mendel and Wakeman salt
mixture and 50 g of water per kilogram of diet. In addition, the drinking water for the H and HSF
groups was supplemented with 25% fructose [14].
4.3. Rat Measurements
Dual-energy X-ray absorptiometry, non-invasive systolic blood pressure, abdominal circumference,
oral glucose and insulin tolerance tests and indirect calorimetry were performed as described [14].
Euthanasia followed by heparin injection, blood collection, centrifugation, storage and then isolated
Langendorff heart preparation and measurements, plasma measurements, organ weights, organ bath
study and histological analyses were performed as described [14].
4.4. Gut Microbiota Analysis
Immediately after euthanasia and organ removal, two or three faecal pellets were collected
from the colon of rats and stored at −80 ◦C in nuclease-free tubes. Total microbial community
DNA was extracted from faecal samples using the DNeasy Powersoil Kit (Qiagen Australia,
Chadstone, VIC, Australia) following the manufacturer’s instructions [45]. The bacterial gut
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microbiota was then characterised by amplifying and sequencing the 16S rRNA gene. The primers,
341F (TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG) and 785R
(GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC) were used
to amplify the V3-V4 regions of the 16S rRNA gene, which was then sequenced on an Illumina MiSeq
platform. Sequencing reads were processed to form zOTUs, which were taxonomically classified
against the SILVA database.
The reaction mixture (50 µL total volume per sample) to amplify the 16S rRNA gene consisted
of Econotaq®PLUS GREEN 2× Master Mix (Astral Scientific, Gymea, NSW, Australia) (25 uL),
Ambion®nuclease-free water (17 µL), the primer pair 341F and 785R (1.5 µL of each; 10 µM) and DNA
template (5 µL). The PCR program consisted of an initial denaturation at 94 ◦C (2 min), followed by
35 cycles of denaturation at 94oC (30 s), annealing at 55oC (30 s), extension at 72 ◦C (40 s) and a final
extension at 72 ◦C (7 min). PCR products were then quantified using gel electrophoresis. Paired-end
sequencing (2 × 300 bp) of the resulting 16S rRNA gene amplicons was performed at the Ramaciotti
Centre for Genomics, University of New South Wales on an Illumina MiSeq platform following the
MiSeq System User Guide [46]. For 16S rRNA gene sequencing analysis, sequence data were initially
quality-filtered and trimmed using Trimmomatic version 0.36 truncating reads if the quality dropped
below 20 in a sliding window of 4 bp [47]. USEARCH version 11.0.667 [48] was used for further
processing [49] to merge and quality-filter sequencing reads, excluding reads with < 250 or > 550
nucleotides, in addition to reads with more than one ambiguous base or an expected error of more than
1. Filtered sequences were denoised and clustered into unique sequences (zero-radius operational
taxonomic units; zOTUs) using the UNOISE algorithm [50] implemented in USEARCH. zOTUs
represent unique bacterial entities and roughly are equivalent to species or strains. Chimeric sequences
were removed de novo during clustering and subsequently in reference mode using UCHIME [51] with
the SILVA database (https://www.arb-silva.de/browser/) (SILVA SSURef 132 NR) as a reference [52].
zOTUs were then taxonomically classified (i.e., assigned a likely taxonomic name) by BLASTN [53]
against the SILVA database. All non-bacterial zOTUs were removed along with non-BLAST aligned
and singleton zOTUs. Finally, processed sequences were mapped on zOTU sequences to calculate
the distribution and counts of each zOTU in every sample. Only zOTUs occurring in more than two
samples were considered for further statistical analysis.
4.5. Statistical Analysis
Physiological and metabolic data are presented as mean ± standard error of the mean (SEM).
These results were tested for variance using Bartlett’s test and variables that were not normally
distributed were transformed using log10 function prior to statistical analyses. Data from the four
groups were tested by two-way analysis of variance. When the interactions and/or the main effects were
significant, means were compared using the Newman-Keuls multiple comparison post hoc test. Where
transformations did not result in normality or constant variance, a Kruskal-Wallis non-parametric test
was performed. A p value of < 0.05 was considered as statistically significant. All statistical analyses
were performed using Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA).
For microbiota results, rarefaction curves were generated using the rarecurve function in vegan [54]
and used to determine if a complete representation of the sample’s microbiota had been achieved
given the sequencing effort. Prior to further analysis, the numbers of sequences were standardised
across samples to account for different sequencing depths by randomly subsampling each sample to
the lowest number of sequences counts obtained for any given sample (i.e., 19,706 counts). Bacterial
alpha-diversities (zOTU richness and Shannon’s diversity) were calculated in R (version 3.5.3) using
the rrarefy function in the vegan package [55]. A one-way analysis of variance test in GraphPad Prism
8.0.2 (San Diego, CA, USA) followed by Tukey’s pairwise comparisons test was used to determine the
significance between the different groups and a p value of <0.05 was considered to be significant.
For multivariate analysis of bacterial communities, zOTU tables were imported into PRIMER [55]
to compare the community structure (i.e. relative abundance data). Bray-Curtis similarity coefficients
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were calculated using square-root transformed zOTU abundances and the resulting similarity matrix
was visualised using non-metric, multi-dimensional scaling (nMDS). Permutational multivariate
analysis of variance (PERMANOVA) [56] with 9,999 random permutations was used to test the effect
of treatment on bacterial communities in rat faecal samples.
5. Conclusions
Rats fed a high-carbohydrate, high-fat diet supplemented with S. filiforme as a source of
ι-carrageenan decreased body weight, systolic blood pressure, abdominal and liver fat and plasma total
cholesterol concentrations compared to H controls. These results are comparable to our previous study
with K. alvarezii as a source of κ-carrageenan, providing evidence that red seaweeds contain compounds
such as sulfated polysaccharides (carrageenans) which attenuate symptoms of diet-induced metabolic
syndrome in rats. The correlations between changes in the gut microbiota and physiological changes
following administration of S. filiforme suggests that the mechanism is likely through carrageenans
acting as prebiotics as well as systemic anti-inflammatory responses in organs such as heart and liver.
Further studies with mechanistic analyses will be valuable to determine the actions of carrageenans
in vivo that are responsible for their health benefits.
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